Gwo-Shu Mary Lee

List of Publications by Year
in descending order

Version: 2024-02-01

20 papers	1,077 citations	623734 14 h-index	713466 21 g-index
21 all docs	21 docs citations	21 times ranked	2117 citing authors

#	Article	IF	Citations
1	Integrative clinical and molecular characterization of translocation renal cell carcinoma. Cell Reports, 2022, 38, 110190.	6.4	40
2	The Impact of PIK3R1 Mutations and Insulinâ€“PI3Kâ€“Glycolytic Pathway Regulation in Prostate Cancer. Clinical Cancer Research, 2022, 28, 3603-3617.	7.0	7
3	Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells. Clinical Cancer Research, 2021, 27, 2087-2099.	7.0	15
4	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nature Communications, 2021, 12, 808.	12.8	84
5	A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer. Prostate, 2021, 81, 683-693.	2.3	5
6	Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nature Genetics, 2020, 52, 790-799.	21.4	174
7	Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer. Molecular Oncology, 2020, 14, 1881-1897.	4.6	22
8	Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Nature Medicine, 2020, 26, 1041-1043.	30.7	161
9	Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma. Genetics in Medicine, 2020, 22, 1366-1373.	2.4	40
10	Methylationâ€associated miRâ€193b silencing activates master drivers of aggressive prostate cancer. Molecular Oncology, 2019, 13, 1944-1958.	4.6	17
11	A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2). Clinical Cancer Research, 2019, 25, 4480-4492.	7.0	96
12	Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 584-590.	2.5	8
13	Low Expression of the Androgen-Induced Tumor Suppressor Gene PLZF and Lethal Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 707-714.	2.5	11
14	ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D. Journal of Clinical Investigation, 2018, 128, 2979-2995.	8.2	53
15	Selenium- or Vitamin Eâ€“Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1050-1058.	2.5	55
16	Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 6259-6264.	7.1	127
17	Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer. JAMA Oncology, 2015, 1, 495.	7.1	118
18	Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Antiâ€“Prostate Cancer Activity. Clinical Cancer Research, 2015, 21, 5578-5587.	7.0	15

#	Article	IF	Citations
19	The Role of miRNAs in Prostate Cancer. European Urology, 2015, 68, 589-590.	1.9	12
20	Emerging players in prostate cancer: long non-coding RNAs. American Journal of Clinical and Experimental Urology, 2014, 2, 294-9.	0.4	11